Tags

Type your tag names separated by a space and hit enter

Drug repositioning in Alzheimer's disease.
Front Biosci (Schol Ed) 2015; 7:184-8FB

Abstract

Drug repositioning offers an innovative approach to drug discovery with great potential in the field of Alzheimer's Disease and dementia therapeutics. Investigation of licensed compounds enables processing through the drug discovery pipeline in a rapid and cost-effective manner. A growing body of evidence supports the translation of priority compounds to be taken forward to clinical trials, based on established and proposed mechanisms of action. A number of drugs have already entered clinical trial following repositioning, and novel technologies have been created to enable high-throughput screening. This review discusses the novel approaches that build on transcriptional signature profiling to support repositioning in AD, and the novel candidate drugs that are emerging from this exciting new technique.

Authors+Show Affiliations

Wolfson Centre for Age-Related Diseases, King's College London, London SE1 1UL, anne.corbett@kcl.ac.uk.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

25961694

Citation

Corbett, Anne, et al. "Drug Repositioning in Alzheimer's Disease." Frontiers in Bioscience (Scholar Edition), vol. 7, 2015, pp. 184-8.
Corbett A, Williams G, Ballard C. Drug repositioning in Alzheimer's disease. Front Biosci (Schol Ed). 2015;7:184-8.
Corbett, A., Williams, G., & Ballard, C. (2015). Drug repositioning in Alzheimer's disease. Frontiers in Bioscience (Scholar Edition), 7, pp. 184-8.
Corbett A, Williams G, Ballard C. Drug Repositioning in Alzheimer's Disease. Front Biosci (Schol Ed). 2015 Jun 1;7:184-8. PubMed PMID: 25961694.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Drug repositioning in Alzheimer's disease. AU - Corbett,Anne, AU - Williams,Gareth, AU - Ballard,Clive, Y1 - 2015/06/01/ PY - 2015/5/12/entrez PY - 2015/5/12/pubmed PY - 2015/9/24/medline SP - 184 EP - 8 JF - Frontiers in bioscience (Scholar edition) JO - Front Biosci (Schol Ed) VL - 7 N2 - Drug repositioning offers an innovative approach to drug discovery with great potential in the field of Alzheimer's Disease and dementia therapeutics. Investigation of licensed compounds enables processing through the drug discovery pipeline in a rapid and cost-effective manner. A growing body of evidence supports the translation of priority compounds to be taken forward to clinical trials, based on established and proposed mechanisms of action. A number of drugs have already entered clinical trial following repositioning, and novel technologies have been created to enable high-throughput screening. This review discusses the novel approaches that build on transcriptional signature profiling to support repositioning in AD, and the novel candidate drugs that are emerging from this exciting new technique. SN - 1945-0524 UR - https://www.unboundmedicine.com/medline/citation/25961694/Drug_repositioning_in_Alzheimer's_disease_ L2 - https://www.bioscience.org/2015/v7s/af/432/fulltext.htm DB - PRIME DP - Unbound Medicine ER -